University of Nottingham

Promethean Particles Ltd. specializes in designing, developing, and manufacturing inorganic nanoparticle dispersions tailored to customer specifications. Established in 2007 and based in Nottingham, United Kingdom, the company employs continuous hydrothermal synthesis to produce high-quality nanoparticles for various industrial applications. Promethean serves multiple sectors, including electronics, healthcare, green energy, and nanocomposites, providing solutions such as printed electronics, catalysts, and metal organic frameworks. Additionally, the company offers feasibility studies to create customized solutions that meet specific client needs. Promethean's advanced multi-ton scale manufacturing plant allows for the production of over 1,000 tons of nanoparticles annually, underscoring its capability to deliver flexible and innovative nanotechnology solutions.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research, promoting more efficient and ethical cell culture experiments. Backed by prominent UK research councils, Peptimatrix brings together experts in matrix biology, cancer science, toxicology, and biomaterial engineering to create reproducible, reliable, and ethical in vitro disease and development models.

The National Biofilms Innovation Centre (NBIC) serves as a collaborative hub uniting academia, industry, government, and public policy to address the challenges posed by biofilms, which significantly impact global economic activity across sectors such as food, health, shipping, clean water, and energy. Supported by funding from the BBSRC, Innovate UK, and Hartree Centre, NBIC's mission focuses on fostering a network for research and innovation that catalyzes partnerships with industry to drive breakthrough innovations. The Centre facilitates the exploration of unmet needs and the exchange of ideas through various initiatives, including roadmaps, workshops, and conferences. Additionally, NBIC is dedicated to nurturing the next generation of scientists through PhD and Post-Doc programs, alongside entrepreneurial training, aimed at enhancing their expertise and understanding of the commercial landscape while promoting the creation of new start-ups.

PBD Biotech Ltd specializes in innovative phage-based diagnostic technology focused on veterinary diagnostics. Established in 2014 and based in Thurston, United Kingdom, the company has developed Actiphage, a diagnostic tool that detects mycobacteria, including Mycobacterium bovis, which is responsible for bovine tuberculosis, and Mycobacterium avium subsp. paratuberculosis, linked to significant agricultural losses. This technology allows for the detection of mycobacteria in milk and blood samples, distinguishing between viable and non-viable bacteria with high sensitivity and specificity. PBD Biotech's advancements enable clinicians to accurately identify low levels of mycobacteria in various animal tissues and food products, enhancing the management of tuberculosis in both livestock and human health contexts.

Operator of a biotechnology company intended to develop safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies. The company aims for therapeutic applications in diseases with high unmet clinical needs such as fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), liver and kidney disease and cancer, enabling patients affected by life-limiting conditions to access effective treatments and relief.

Cheesecake Energy specializes in the development of advanced thermal and compressed air energy systems that facilitate the storage of energy from intermittent renewable sources. By converting this stored energy into reliable power on demand, the company addresses the challenges associated with renewable energy variability. Cheesecake Energy's technology employs a combination of compressed air and thermal energy storage, utilizing industrial components that are readily available in the market. This approach not only enhances the durability of the storage systems but also allows clients to acquire these devices at a competitive price, making renewable energy more accessible and dependable.

NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.

One Third Stories is a business focused on language learning for children, utilizing an innovative approach known as the Clockwork Methodology®. The company offers a monthly subscription box that includes engaging stories designed to start in English and conclude in a different language. This unique format aims to make language acquisition enjoyable and accessible for young learners, providing parents with a resource to support their children's education. By transforming the process of learning into a storytelling adventure, One Third Stories seeks to foster a love for languages in children through simple and interactive narratives.

NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.

One Third Stories is a business focused on language learning for children, utilizing an innovative approach known as the Clockwork Methodology®. The company offers a monthly subscription box that includes engaging stories designed to start in English and conclude in a different language. This unique format aims to make language acquisition enjoyable and accessible for young learners, providing parents with a resource to support their children's education. By transforming the process of learning into a storytelling adventure, One Third Stories seeks to foster a love for languages in children through simple and interactive narratives.

Monica Healthcare specializes in the manufacturing and supply of advanced fetal monitoring devices aimed at improving obstetric care for midwives, labor and delivery nurses, and expectant mothers. The company’s flagship product, The Novii, is a single-use wireless patch system that monitors maternal heart rate, fetal heart rate, and uterine activity, enhancing the birthing experience. Additionally, Monica Healthcare develops a range of wearable devices that utilize innovative wireless technologies to provide accessible obstetric services both in hospitals and at home. The company also offers training, repairs, and support services for its products. Established in 2005 and headquartered in Nottingham, United Kingdom, with a location in Kennesaw, Georgia, Monica Healthcare operates as a subsidiary of GE Healthcare.

Exonate Limited is a private biotech company based in Duxford, United Kingdom, specializing in the discovery and development of small molecule drugs aimed at modulating alternative messenger RNA splicing for ophthalmological applications. Founded in 2013, the company emerged from the University of Nottingham and is focused on addressing retinal vascular diseases, particularly diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD). Exonate's lead program utilizes small molecule inhibitors that selectively target serine/threonine-protein kinase 1 to inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) splice variants. This innovative approach aims to improve therapeutic outcomes and offers a potential alternative to current treatment methods, such as anti-VEGF injections and laser surgery. With a preclinical candidate drug already nominated, Exonate is advancing its research through regulatory toxicology and safety pharmacology studies to facilitate clinical evaluation. The company is backed by an experienced management team with expertise in medicine and drug development.

Monica Healthcare specializes in the manufacturing and supply of advanced fetal monitoring devices aimed at improving obstetric care for midwives, labor and delivery nurses, and expectant mothers. The company’s flagship product, The Novii, is a single-use wireless patch system that monitors maternal heart rate, fetal heart rate, and uterine activity, enhancing the birthing experience. Additionally, Monica Healthcare develops a range of wearable devices that utilize innovative wireless technologies to provide accessible obstetric services both in hospitals and at home. The company also offers training, repairs, and support services for its products. Established in 2005 and headquartered in Nottingham, United Kingdom, with a location in Kennesaw, Georgia, Monica Healthcare operates as a subsidiary of GE Healthcare.

Critical Pharmaceuticals Limited is a biotechnology company based in Nottingham, United Kingdom, that specializes in the development of biological drug products using innovative drug delivery technologies. Founded in 2002 by Professor Steve Howdle, the company focuses on non-invasive nasal delivery and sustained release formulations for proteins, peptides, and small molecules. Its proprietary technologies, CriticalSorb and CriticalMix, facilitate the nasal delivery of biologics and the manufacture of depot products that allow for infrequent injections. The company's product pipeline includes CP024, a nasal growth hormone for growth hormone deficiency; CP046, a nasal treatment for osteoporosis; and CP057, a sustained-release formulation of Bevacizumab for age-related macular degeneration, among others. However, as of July 31, 2017, Critical Pharmaceuticals Limited has entered liquidation.